Lexeo Therapeutics (LXEO) RBC Capital Markets Global Healthcare Conference 2025 summary

Recent progress and future outlook

• Two clinical-stage cardiac genetic medicine programs are advancing, with the Friedreich's ataxia (FA) program moving from phase I/II to a registration study and showing promising data for accelerated approval.

• The arrhythmogenic cardiomyopathy (PKP2) program is in phase I, targeting a large patient population and leveraging recent clinical and preclinical proof of concept.

• Regulatory engagement with the FDA remains constructive, with no major changes in approach for rare and gene therapy sectors.

• The company is preparing to launch a natural history study this quarter to support faster and de-risked enrollment for the pivotal FA trial.

• Cash runway is guided into 2027, with cost reductions implemented and options for further financing, including equity and partnerships.

Clinical data and trial design

• FA therapy has demonstrated a 25% reduction in left ventricular mass index (LVMI) at 12 months, exceeding the 10% threshold associated with improved outcomes.

• Benefits are most pronounced in patients with abnormal baseline LVMI, but improvements in troponin and wall thickness are also seen in those with normal LVMI.

• The pivotal FA trial will use LVMI as the primary endpoint, with a natural history study for propensity matching and faster enrollment.

• The PKP2 program is using higher doses due to the need for structural protein restoration, with a favorable safety profile observed so far.

• Rapamycin is used for immune suppression in PKP2, with no complement-mediated toxicity observed, and the regimen is considered safer than alternatives.

Regulatory and market strategy

• FDA has accepted LVMI as a primary endpoint for FA, with troponin and wall thickness as secondary endpoints; a broad label is sought based on improvements across measures.

• The pivotal FA trial is expected to start in early 2026, with statistical plans being finalized.

• For PKP2, endpoints may include expression and reduction in premature ventricular contractions, with further definition pending additional data and FDA discussions.

• The PKP2 market is large for a rare disease, potentially supporting multiple therapies, with product profile and safety as key differentiators.

• Financing strategies include cost controls, non-dilutive capital, and potential geographic partnerships to supplement the balance sheet.